Intensity Therapeutics of Westport has established a cooperative research and development agreement with the National Institute of Health’s National Cancer Institute Vaccine Branch. The company was awarded the agreement to study the efficacy and mechanism of action of Intensity’s in situ chemovaccination products using in vivo models of cancer.
“We are pleased to be collaborating with the world’s leading cancer research organization, the National Cancer Institute,” said Lewis H. Bender, President and CEO of Intensity Therapeutics.
— UPCOMING EVENTS —
6/5 4:00 pm – 6:00 pm in New Haven
CURE annual meeting and BioHaven panel discussion: “Growing Connecticut’s Bioscience Community: Supporting Ideas, Creating Value” … more
6/16 4:30 pm – 6:00 pm in Farmington
BioScienceClubhouseCT presents ‘CORNOVUS Pharmaceuticals: Novel Treatment for Heart Failure’ … more